GlassScriptPhysician profile
Shariq Ahmad
NPI 1861490211
$762.55
in general payments reported to CMS, 2019-2025
14 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.73 · 2022: $201 · 2023: $106 · 2024: $163 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $132.63 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $112.49 | 2019-2022 | |
| Amgen INC. | $83.52 | 2024-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $79.41 | 2022-2024 | Jynarque |
| Ethicon US, LLC | $78.57 | 2019 | |
| Ani Pharmaceuticals, INC. | $70.01 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $41.61 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $37.82 | 2023-2024 | Pureflow Sl |
| Travere Therapeutics, INC. | $32.35 | 2023 | |
| Cormedix INC. | $22.46 | 2024 | Defencath |
| Calliditas Therapeutics US INC. | $18.85 | 2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $18.04 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.55 | 2024 | |
| Vifor Pharma, INC. | $17.24 | 2025 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shariq Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.